Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results